MET and non-small cell lung carcinoma: For example, the typically favorable genes in NSCLC are TP53 (tumor protein p53), KRAS (KRAS proto-oncogene, GTPase), etc. Common negative genes include EGFR (epidermal growth factor receptor), MET (MET proto-oncogene, receptor tyrosine kinase), ALK (ALK receptor tyrosine kinase), etc. Patients with favorable gene mutations will have better therapeutic effects when receiving immunotherapy, while patients with negative gene mutations will have poorer efficacy.